Hester Biosciences Limited has informed the Exchange regarding Proceedings of undefined held on March 09, 2026. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report together with copy of minutes.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences sought shareholder approval via postal ballot (remote e-voting from 8 February to 9 March 2026) for the re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term from 1 April 2026 to 31 March 2029. The special resolution was passed with overwhelming support: 99.54% of votes in favour (40,56,419 shares from 76 voters) versus just 0.46% against (18,666 shares from 11 voters), out of 40,75,085 total valid shares polled. The promoter group voted 100% in favour (34.51 lakh shares), public non-institutional shareholders backed it 99.98%, while a small set of institutional holders dissented (99.24% of their polled shares against, though only 18,570 shares in absolute terms). Overall, 47.90% of the company's outstanding equity shares participated in the voting.
Leadership continuity is secured with near-unanimous shareholder backing, signalling strong confidence in the incumbent CEO and likely a non-event for the stock. The institutional dissent is numerically tiny but worth tracking as a sentiment flag from sophisticated investors.